1. 1 Harris NL, Swerdlow SH. Methotrexate-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed, Lyon, IARC. 2001; pp. 270-271.
2. 2 Gaulard P, Swerdlow SH, Harris NL, Jaffe ES, Sundstrom C. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. (eds): World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2008; pp. 350-351.
3. 3 Hashimoto A, Chiba N, Tsuno H et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015; 42: 564-571.
4. 4 Gaulard P, Swerdlow SH, Harris NL, Sundstrom C, Jaffe ES. EBV-positive mucocutaneous ulcer. In: Swerdlow SH, Campo E, Harris NL, et al. (eds): World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed, Lyon, IARC. 2017; pp. 307-308.
5. 5 Gion Y, Iwaki N, Takata K et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci. 2017; 108: 1271-1280.